1. Home
  2. CTKB vs TRDA Comparison

CTKB vs TRDA Comparison

Compare CTKB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.93

Market Cap

652.1M

Sector

Health Care

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.07

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
TRDA
Founded
1990
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
652.1M
386.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CTKB
TRDA
Price
$4.93
$10.07
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$5.88
$20.00
AVG Volume (30 Days)
1.2M
167.3K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,828,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.62
$3.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$4.93
52 Week High
$7.30
$18.76

Technical Indicators

Market Signals
Indicator
CTKB
TRDA
Relative Strength Index (RSI) 48.50 48.34
Support Level $4.95 $9.89
Resistance Level $5.18 $10.44
Average True Range (ATR) 0.20 0.51
MACD -0.01 -0.21
Stochastic Oscillator 61.60 11.70

Price Performance

Historical Comparison
CTKB
TRDA

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: